A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)

被引：0
|
作者：
Pili, R.
Haggman, M.
Stadler, W. M.
Gingrich, J. R.
Assikis, V. J.
Bjork, A.
Forsberg, G.
Carducci, M. A.
Armstrong, A. J.
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Peachtree Hematol Oncol, Atlanta, GA USA
[6] Act Biotech, Lund, Sweden
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4510
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    Nemtsova, E. R.
    Pankratov, A. A.
    Morozova, N. B.
    Tischenko, V. K.
    Petriev, V. M.
    Krylov, V. V.
    Shegay, P. V.
    Ivanov, S. A.
    Kaprin, A. D.
    BIOLOGY BULLETIN, 2022, 49 (12) : 2285 - 2297
  • [22] Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer
    Mountzios, Ioannis
    Bournakis, Evangelos
    Efstathiou, Eleni
    Varkaris, Andreas
    Wen, Sijin
    Chrisofos, Michael
    Deliveliotis, Charalambos
    Alamanis, Christos
    Anastasiou, Ioannis
    Constantinides, Constantine
    Karadimou, Alexandra
    Tsiatas, Marinos
    Papadimitriou, Christos
    Bamias, Aristotelis
    Dimopoulos, Meletios A.
    UROLOGY, 2011, 77 (03) : 682 - 687
  • [23] A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67
    Hahn, N. M.
    Zon, R. T.
    Yu, M.
    Ademuyiwa, F. O.
    Jones, T.
    Dugan, W.
    Whalen, C.
    Shanmugam, R.
    Skaar, T.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2009, 20 (12) : 1971 - 1976
  • [24] Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer
    Cheung, F. Y.
    Leung, K. C.
    Ngan, Roger K. C.
    HONG KONG MEDICAL JOURNAL, 2013, 19 (03) : 237 - 241
  • [25] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    E. R. Nemtsova
    A. A. Pankratov
    N. B. Morozova
    V. K. Tischenko
    V. M. Petriev
    V. V. Krylov
    P. V. Shegay
    S. A. Ivanov
    A. D. Kaprin
    Biology Bulletin, 2022, 49 : 2285 - 2297
  • [26] Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P. M.
    Mulquin, M.
    Wright, J. J.
    Turkbey, I. B.
    Choyke, P.
    Ahlers, C. M.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC)
    Halabi, S.
    Kelly, W. K.
    George, D. J.
    Morris, M. J.
    Kaplan, E. B.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [28] Castrate-resistant prostate cancer (CRPC): Prognostic and predictive value of testosterone levels in patients receiving chemotherapy.
    De Liano Lista, Alfonso Gomez
    Reig, Oscar
    Mellado, Begona
    Martin Lorente, Cristina
    Cillan, Elena
    Macias, Ismael
    Sancho, Gemma
    Palou, Joan
    Maroto-Rey, Pablo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Survival and Skeletal-related Events in Metastatic Castrate-resistant Prostate Cancer Patients Fit for Chemotherapy but Bisphosphonate-naive
    Pell, R.
    Harland, S.
    CLINICAL ONCOLOGY, 2014, 26 (02) : E6 - E6
  • [30] Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects
    Mehta, Amit R.
    Armstrong, Andrew J.
    THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (01) : 9 - 18
12345